BMS-202 hydrochloride
Based on 25 publication(s) in Google Scholar
BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.02%
- CAS No.: 2089334-95-0
- Formule: C25H30ClN3O3
- Masse moléculaire:455.98
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) BMS-202 hydrochloride
More- ACS Nano. 2024 Feb 20;18(7):5632-5646. [Abstract]
- Nat Commun. 2021 Dec 9;12(1):7155. [Abstract]
- Acta Pharm Sin B. 2025 Apr;15(4):2156-2169. [Abstract]
- Acta Pharm Sin B. 2022 Apr;12(4):2103-2119. [Abstract]
- Adv Sci (Weinh). 2024 Dec 16:e2409895. [Abstract]
- J Nanobiotechnology. 2023 Oct 3;21(1):360. [Abstract]
- Nano Today. 2022, 47: 101689.
- EBioMedicine. 2019 Mar:41:395-407. [Abstract]
- Biomater Res. 2023 Nov 24;27(1):120. [Abstract]
- Mater Today Nano. 2024 Aug.
- J Med Chem. 2026 Apr 9;69(7):8417-8432. [Abstract]
- J Med Chem. 2025 Jun 12;68(11):11829-11840. [Abstract]
- J Med Chem. 2025 Feb 20. [Abstract]
- J Med Chem. 2020 Nov 25;63(22):13825-13850. [Abstract]
- Cells. 2022 Oct 7;11(19):3152. [Abstract]
- Nanoscale. 2021 Oct 1;13(37):15789-15803. [Abstract]
- ACS Omega. 2023 Sep 3;8(37):33242-33254. [Abstract]
- Drug Dev Res. 2022 Feb;83(1):176-183. [Abstract]
- ACS Pharmacol Transl Sci. 2025 Jul 7;8(8):2612-2629. [Abstract]
- Cell Signal. 2024 Jun 26:111275. [Abstract]
- Mol Med Rep. 2025 Sep;32(3):242. [Abstract]
- Mol Pain. 2024 Jan-Dec:20:17448069241252384. [Abstract]
- Onco Targets Ther. 2021 Mar 30:14:2247-2258. [Abstract]
- Bio Protoc. 2023 Aug 5;13(15):e4765. [Abstract]
- Pharmacological Research-Modern Chinese Medicine. 19 January 2022, 100051.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
Cell Migration/Invasion Assay
-
RT-PCR
-
Flow Cytometry
Activité biologique
Chemical Information
-
CAS No. 2089334-95-0
-
Appearance Solid
-
Masse moléculaire 455.98
-
Formule C25H30ClN3O3
-
Color Off-white to light yellow
-
SMILES
CC(NCCNCC1=CC=C(OCC2=C(C)C(C3=CC=CC=C3)=CC=C2)N=C1OC)=O.[H]Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (25)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
Immunomodulatory Prodrug Micelles Imitate Mild Heat Effects to Reshape Tumor Microenvironment for Enhanced Cancer Immunotherapy. [Abstract]2024 Feb 20;18(7):5632-5646. PMID: 38344992 -
Nat Commun
Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment. [Abstract]2021 Dec 9;12(1):7155. PMID: 34887423 -
Acta Pharm Sin B
GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins. [Abstract]2025 Apr;15(4):2156-2169. PMID: 40486834
BMS-202 hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Apr;15(4):2156-2169. [Abstract]
Effects of compounds WP0 and BMS-202 to induce T-cell-mediated tumor killing against HepG2 Cells.
BMS-202 hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Apr;15(4):2156-2169. [Abstract]
PD-L1 protein level in HepG2 cells. Cells were pretreated with lysosome inhibitor BafA (100 nmol/L), BMS-202 (1 μmol/L), TJ12P1 (1 μmol/L), or proteasome inhibitor MG132 (100 nmol/L), followed by treatment with WP0 (1 μmol/L).
-
Acta Pharm Sin B
Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy. [Abstract]2022 Apr;12(4):2103-2119. PMID: 35847496 -
Adv Sci (Weinh)
Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy. [Abstract]2024 Dec 16:e2409895. PMID: 39679804 -
J Nanobiotechnology
Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA. [Abstract]2023 Oct 3;21(1):360. PMID: 37789342 -
-
EBioMedicine
2019 Mar:41:395-407. PMID: 30803931 -
Biomater Res
Metal-organic framework-based photodynamic combined immunotherapy against the distant development of triple-negative breast cancer. [Abstract]2023 Nov 24;27(1):120. PMID: 37996880
BMS-202 hydrochloride purchased from MedChemExpress. Usage Cited in: Biomater Res. 2023 Nov 24;27(1):120. [Abstract]
Compared with the blank control group, the PCN-224/HP NPs, BMS-202, BMS@P/HP NPs, PCN-224/HP+L and BMS@P/HP+L groups all showed different degrees of tumor cell apoptosis.
-
-
J Med Chem
Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of Intracellular and Extracellular Proteins. [Abstract]2026 Apr 9;69(7):8417-8432. PMID: 41874277 -
J Med Chem
2025 Jun 12;68(11):11829-11840. PMID: 40403183 -
J Med Chem
Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy. [Abstract]2025 Feb 20. PMID: 39979078 -
J Med Chem
Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo. [Abstract]2020 Nov 25;63(22):13825-13850. PMID: 33186040 -
Cells
Immunomodulatory Effect and Bone Homeostasis Regulation in Osteoblasts Differentiated from hADMSCs via the PD-1/PD-L1 Axis. [Abstract]2022 Oct 7;11(19):3152. PMID: 36231113 -
Nanoscale
Adoptive CD8+T-cell grafted with liposomal immunotherapy drugs to counteract the immune suppressive tumor microenvironment and enhance therapy for melanoma. [Abstract]2021 Oct 1;13(37):15789-15803. PMID: 34528979 -
ACS Omega
Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents. [Abstract]2023 Sep 3;8(37):33242-33254. PMID: 37744828 -
Drug Dev Res
The PD-1/PD-L1 binding inhibitor BMS-202 suppresses the synthesis and secretion of gonadotropins and enhances apoptosis via p38 MAPK signaling pathway. [Abstract]2022 Feb;83(1):176-183. PMID: 34309063
BMS-202 hydrochloride purchased from MedChemExpress. Usage Cited in: Drug Dev Res. 2022 Feb;83(1):176-183. [Abstract]
Cultured Lβt2 cells are treated with 25 μM BMS-202 and collected at 24 h. the p-p38 MAPK, p38 MAPK, p-JNK, JNK, p-ERK, ERK, and α-tubulin protein levels are detected by Western Blotting.
-
ACS Pharmacol Transl Sci
Antineuroblastoma Activity Evaluation and Mechanism of Novel PD-L1 Small Molecule Inhibitors through Immune and Non-Immune Pathways. [Abstract]2025 Jul 7;8(8):2612-2629. PMID: 40810160 -
Cell Signal
2024 Jun 26:111275. PMID: 38942343 -
Mol Med Rep
Direct effects of the small molecule PD‑L1 inhibitor BMS‑202 on A375 melanoma cells: Anti‑tumor activity accompanied by increased mitochondrial function. [Abstract]2025 Sep;32(3):242. PMID: 40641134
BMS-202 hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2025 Sep;32(3):242. [Abstract]
BMS-202 (5 μM, 24 h) inhibits A375 cell migration and invasion.
BMS-202 hydrochloride purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2025 Sep;32(3):242. [Abstract]
RT-qPCR analysis revealed an increase in the mRNA expression levels of the pro-apoptotic factor Bax and a decrease in the mRNA expression levels of the anti-apoptotic factor Bcl-2 treated with BMS-202 (5 μM, 24 h).
-
Mol Pain
The regulation of the PD-1/PD-L1 pathway in imiquimod-induced chronic psoriasis itch and itch sensitization in mouse. [Abstract]2024 Jan-Dec:20:17448069241252384. PMID: 38631843 -
Onco Targets Ther
Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette-Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model. [Abstract]2021 Mar 30:14:2247-2258. PMID: 33833524 -
Bio Protoc
Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor. [Abstract]2023 Aug 5;13(15):e4765. PMID: 37575393 -
Solvant et solubilité
H2O : ≥ 100 mg/mL (219.31 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (269 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zak KM, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016 May 24;7(21):30323-35. [Content Brief]
[2]. Ashizawa T, et al. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomed Res. 2019;40(6):243-250. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.1931 mL | 10.9654 mL | 21.9308 mL | 54.8270 mL |
| 5 mM | 0.4386 mL | 2.1931 mL | 4.3862 mL | 10.9654 mL | |
| 10 mM | 0.2193 mL | 1.0965 mL | 2.1931 mL | 5.4827 mL | |
| 15 mM | 0.1462 mL | 0.7310 mL | 1.4621 mL | 3.6551 mL | |
| 20 mM | 0.1097 mL | 0.5483 mL | 1.0965 mL | 2.7413 mL | |
| 25 mM | 0.0877 mL | 0.4386 mL | 0.8772 mL | 2.1931 mL | |
| 30 mM | 0.0731 mL | 0.3655 mL | 0.7310 mL | 1.8276 mL | |
| 40 mM | 0.0548 mL | 0.2741 mL | 0.5483 mL | 1.3707 mL | |
| 50 mM | 0.0439 mL | 0.2193 mL | 0.4386 mL | 1.0965 mL | |
| 60 mM | 0.0366 mL | 0.1828 mL | 0.3655 mL | 0.9138 mL | |
| 80 mM | 0.0274 mL | 0.1371 mL | 0.2741 mL | 0.6853 mL | |
| 100 mM | 0.0219 mL | 0.1097 mL | 0.2193 mL | 0.5483 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz